Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

References

• Chen W , Zheng R , Baade PD , et al. Cancer statistics in China, 2015. CA Cancer J Clin . 2016;66(2):115–132. doi:10.3322/caac.21338 26808342
   PubMed Web of Science ®Google Scholar
• Chen Y , Liu MZ , Liang SB , et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys . 2008;71(5):1356–1364. doi:10.1016/j.ijrobp.2007.12.028 18472356
   PubMed Web of Science ®Google Scholar
• Peng G , Wang T , Yang KY , et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol . 2012;104(3):286–293. doi:10.1016/j.radonc.2012.08.013 22995588
   PubMed Web of Science ®Google Scholar
• Ng WT , Lee MC , Hung WM , et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys . 2011;79(2):420–428. doi:10.1016/j.ijrobp.2009.11.024 20452132
   PubMed Web of Science ®Google Scholar
• Zhang MX , Li J , Shen GP , et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer . 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.006 26318726
   PubMed Web of Science ®Google Scholar
• Gihbid A , Benzeid R , Faouzi A , et al. Circulating cell-free epstein-barr virus DNA levels and clinical features in Moroccan patients with nasopharyngeal carcinoma. Infect Agent Cancer . 2021;16(1):15. doi:10.1186/s13027-021-00353-8 33602309
   PubMed Web of Science ®Google Scholar
• Feng Y , Zhang N , Wang S , et al. Systemic inflammation response index is a predictor of poor survival in locally advanced nasopharyngeal carcinoma: a propensity score matching study. Front Oncol . 2020;10:575417. doi:10.3389/fonc.2020.575417 33363009
   PubMed Web of Science ®Google Scholar
• Trevisiol C , Gion M , Vaona A , et al. The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: comprehensive clinical practice guidelines evaluation. Oral Oncol . 2021;114:105128. doi:10.1016/j.oraloncology.2020.105128 33444925
   PubMed Web of Science ®Google Scholar
• Schmidt A , Weber OF . In memoriam of Rudolf virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol . 2006;13:1–15. doi:10.1159/000092961 16627956
   PubMedGoogle Scholar
• Coussens LM , Werb Z . Inflammation and cancer. Nature . 2002;420(6917):860–867. doi:10.1038/nature01322 12490959
   PubMed Web of Science ®Google Scholar
• Wang L , Zhou Y , Xia S , et al. Prognostic value of the systemic inflammation response index (SIRI) before and after surgery in operable breast cancer patients. Cancer Biomark . 2020;28(4):537–547. doi:10.3233/CBM-201682 32568185
   PubMed Web of Science ®Google Scholar
• Hu M , Xu Q , Yang S , et al. Pretreatment systemic inflammation response index (SIRI) is an independent predictor of survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy: a two-center retrospective study. Ann Transl Med . 2020;8(20):1310. doi:10.21037/atm-20-6484 33209890
   PubMed Web of Science ®Google Scholar
• Pacheco-Barcia V , Mondejar SR , France T , et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology . 2020;20(2):254–264. doi:10.1016/j.pan.2019.12.010 31866391
   PubMed Web of Science ®Google Scholar
• Chao B , Ju X , Zhang L , Xu X , Zhao Y . A novel prognostic marker Systemic Inflammation Response Index (SIRI) for operable cervical cancer patients. Front Oncol . 2020;10:766. doi:10.3389/fonc.2020.00766 32477958
   PubMed Web of Science ®Google Scholar
• Bulut G , Ozdemir ZN . Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in metastatic colorectal cancer. J Gastrointest Cancer . In Press 2021. doi:10.1007/s12029-021-00616-y
   Web of Science ®Google Scholar
• Wolfe AR , Siedow M , Nalin A , et al. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiother Oncol . 2021;158:207–214. doi:10.1016/j.radonc.2021.02.035 33667588
   PubMed Web of Science ®Google Scholar
• Mollinedo F . Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol . 2019;40(3):228–242. doi:10.1016/j.it.2019.01.006 30777721
   PubMed Web of Science ®Google Scholar
• Zeng X , Liu G , Pan Y , Li Y . Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med . 2020;24(15):8326–8349. doi:10.1111/jcmm.15097 32603520
   PubMed Web of Science ®Google Scholar
• Ferrone C , Dranoff G . Dual roles for immunity in gastrointestinal cancers. J Clin Oncol . 2010;28(26):4045–4051. doi:10.1200/JCO.2010.27.9992 20644090
   PubMed Web of Science ®Google Scholar
• Zhang Y , Liu F , Wang Y . Evidence of the prognostic value of pretreatment systemic inflammation response index in cancer patients: a pooled analysis of 19 cohort studies. Dis Markers . 2020;2020:8854267. doi:10.1155/2020/8854267 32934755
   PubMed Web of Science ®Google Scholar
• Topkan E , Selek U , Kucuk A , et al. Prechemoradiotherapy systemic inflammation response index stratifies stage iIIB/C non-small-cell lung cancer patients into three prognostic groups: a propensity score-matching analysis. J Oncol . 2021;2021:6688138. doi:10.1155/2021/6688138 33552158
   PubMed Web of Science ®Google Scholar
• Chuang HC , Tsai MH , Lin YT , et al. The clinical impacts of pretreatment peripheral blood ratio on lymphocytes, monocytes, and neutrophils among patients with laryngeal/hypopharyngeal cancer treated by chemoradiation/radiation. Cancer Manag Res . 2020;12:9013–9021. doi:10.2147/CMAR.S275635 33061596
   PubMed Web of Science ®Google Scholar
• Lu A , Li H , Zheng Y , et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int . 2017;2017:3047802. doi:10.1155/2017/3047802 28321405
   PubMed Web of Science ®Google Scholar
• Ye L , Oei RW , Kong F , et al. Prognostic values of hematological biomarkers in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Eur Arch Otorhinolaryngol . 2018;275(5):1309–1317. doi:10.1007/s00405-018-4956-x 29589142
   PubMed Web of Science ®Google Scholar
• Li XH , Chang H , Xu BQ , et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Med . 2017;6(1):310–319. doi:10.1002/cam4.947 27860387
   PubMed Web of Science ®Google Scholar
• Yang R , Chang Q , Meng X , Gao N , Wang W . Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer . 2018;9(18):3295–3302. doi:10.7150/jca.25691 30271489
   PubMed Web of Science ®Google Scholar
• Jiang W , Chen Y , Huang J , et al. Systemic immune-inflammation index predicts the clinical outcome in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. Oncotarget . 2017;8(39):66075–66086. doi:10.18632/oncotarget.19796 29029493
   PubMedGoogle Scholar
• Oei RW , Ye L , Kong F , et al. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study. Cancer Manag Res . 2018;10:2785–2797. doi:10.2147/CMAR.S171239 30147375
   PubMed Web of Science ®Google Scholar
• Qi Q , Zhuang L , Shen Y , et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer . 2016;122(14):2158–2167. doi:10.1002/cncr.30057 27152949
   PubMed Web of Science ®Google Scholar
• Chen Y , Jiang W , Xi D , et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. J Investig Med . 2019;67(3):691–698. doi:10.1136/jim-2018-000801
   PubMed Web of Science ®Google Scholar
• Huang SJ , Tang YY , Liu HM , et al. Impact of age on survival of locoregional nasopharyngeal carcinoma: an analysis of the surveillance, epidemiology, and end results program database, 2004–2013. Clin Otolaryngol . 2018;43(5):1209–1218. doi:10.1111/coa.13124 29688619
   PubMed Web of Science ®Google Scholar
• Wu SG , Liao XL , He ZY , et al. Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: a population-based analysis. Oral Oncol . 2017;73:83–87. doi:10.1016/j.oraloncology.2017.08.006 28939081
   PubMed Web of Science ®Google Scholar
• Li AC , Xiao WW , Shen GZ , et al. Distant metastasis risk and patterns of nasopharyngeal carcinoma in the era of IMRT: long-term results and benefits of chemotherapy. Oncotarget . 2015;6(27):24511–24521. doi:10.18632/oncotarget.4312 26087194
   PubMedGoogle Scholar
• Loong HH , Ma BB , Chan AT . Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. Hematol Oncol Clin North Am . 2008;22(6):1267–1278. doi:10.1016/j.hoc.2008.08.012 19010273
   PubMed Web of Science ®Google Scholar
• Jiang R , Zou X , Hu W , et al. The elevated pretreatment platelet-to-lymphocyte ratio predicts poor outcome in nasopharyngeal carcinoma patients. Tumour Biol . 2015;36(10):7775–7787. doi:10.1007/s13277-015-3505-0 25944165
   PubMedGoogle Scholar
• Li JP , Chen SL , Peng SG , et al. Prognostic nomogram for patients with nasopharyngeal carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci . 2018;14(5):549–556. doi:10.7150/ijbs.24374 29805306
   PubMed Web of Science ®Google Scholar
• Xiong Y , Shi LL , Zhu LS , et al. Prognostic efficacy of the combination of the pretreatment systemic immune-inflammation index and epstein-barr virus DNA status in locally advanced nasopharyngeal carcinoma patients. J Cancer . 2021;12(8):2275–2284. doi:10.7150/jca.52539 33758605
   PubMed Web of Science ®Google Scholar